Hypertension November 2016

Slides:



Advertisements
Similar presentations
Commissioning for Value 24 th March 2015 Dr Stephen Liversedge NHS Bolton CCG.
Advertisements

National Institute for Health and Clinical Excellence.
Update on hypertension - diagnosis, monitoring and guideline treatment targets Prof. Richard McManus, Birmingham, United Kingdom.
Valsartan Antihypertensive Long-Term Use Evaluation Results
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Heart Disease Map.
Healthy People 2010 Focus Area 12: Heart Disease and Stroke
Chronic kidney disease Mr James Hollinshead Public Health Analyst East Midlands Public Health Observatory (EMPHO) UK Renal Registry 2011 Annual Audit Meeting.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Implementing NICE guidance
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
Inequalities in coronary heart disease treatment Professor Azeem Majeed University College London.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Improving the Quality of Physical Health Checks
Association between Systolic Blood Pressure and Congestive Heart Failure in Hypertensive Patients Mrs. Sutheera Intajarurnsan Doctor of Public Health Student.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Improving the Quality of Physical Health Checks Kate Dale, Mental/Physical Health Lead BDCT.
Nurse Co-ordinated Rapid Access Chest Pain Clinic
1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008.
Doran Paying Physicians for Quality Primary Care Reform in the UK Tim Doran National Primary Care Research and Development Centre University of Manchester.
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
Association between Systolic Blood Pressure and Congestive Heart Failure Complication among Hypertensive and Diabetic Hypertensive Patients Mrs. Sutheera.
Presented by Paul Wright MRPSII MRPha rmS Lead Cardiac Pharmacist, Barts Heart Centre, Barts Health NHS Trust Workshop written and prepared by Helen Williams.
Using QOF and Service Specifications to meet HI Needs Rachel Foskett-Tharby.
VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
References 1.Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
Angela Aziz Donnelly April 5, 2016
Cardiovascular Risk: A global perspective
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Management of Hypertension according to JNC 7
Dr John Cox Diabetes in Primary Care Conference Cork
Clinical Management of primary hypertension
Health checks for people with learning disabilities Primary Care Development Presentation for Locality Meetings January 2017 Martin.
What should the Systolic BP treatment goal be in patients with CKD?
Nephrology Journal Club The SPRINT Trial Parker Gregg
Tackling High Blood Pressure Through Community Pharmacy
Hypertension November 2016
From ESH 2016 | POS 3C: Chiara Lorenzi, MD
John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
Changing demographics and the impact on dementia
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Improving Chronic Care Management
Cardiovascular risk factors: are they useful screening tests?
Teaching Tool: Blood Pressure Classification
Local Tobacco Control Profiles The webinar will start at 1pm
Systolic Blood Pressure Intervention Trial (SPRINT)
MANAGING KIDNEY DISEASE IN PRIMARY CARE
Helen O’Kelly Health service engagement lead, south east
Principal recommendations
Atrial Fibrillation Local data and data tools: February 2016
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Goals & Guidelines A summary of international guidelines for CHD
Value Based Healthcare King’s Health Partners
2017/18 National Diabetes Audit Cambridgeshire and Peterborough CCG local summary Public Health Intelligence, Cambridgeshire and Peterborough : April 2019.
Hypertension Implementing NICE guidance 2 nd Edition March 2013 NICE clinical guideline 127.
DRAFT Granta Data pack January 2019.
High Blood Pressure, the Silent Killer: How Can We Do better in Wales?
Tools to support development of interventions Soili Larkin & Mohammed Vaqar Public Health England West Midlands.
Presentation transcript:

Hypertension November 2016 Helen Williams, Consultant Pharmacist for Cardiovascular Disease Anna Hodgkinson, Senior Clinical Commissioning Pharmacist November 2016

Hypertension High blood pressure (hypertension) (>140/90mmHg) is one of the most important preventable causes of premature morbidity and mortality in the UK Major risk factor for stroke, heart attacks, heart failure, chronic kidney disease, cognitive decline and premature death Risk associated with increasing blood pressure (BP) is continuous - each 2 mmHg rise in systolic blood pressure associated with a 7% increased risk of mortality from ischaemic heart disease and a 10% increased risk of mortality from stroke People from the most deprived areas are 30% more likely than the least-deprived to have high blood pressure, and the condition disproportionately affects some ethnic groups including black Africans and Caribbean Blood pressure is normally distributed in the population and there is no natural cut-off point above which 'hypertension' definitively exists and below which it does not. https://www.nice.org.uk/guidance/cg127/chapter/Introduction Systolic BP – top number Diastolic BP – bottom number Given deprivation and ethnic mix in Lambeth, HYPERTENSION IS THEREFORE A PRIORITY

Hypertension: Equality objective Part one – to obtain a snapshot profile of the age, sex and ethnicity of people registered with Lambeth GP practices diagnosed with hypertension with both controlled and uncontrolled hypertension Part two – to identify if interventions currently in place for hypertension management meet the needs of our population looking specifically at age, ethnicity and sex

Part one Baseline analysis (31st December 2015) demonstrated that those less likely to have adequate BP control were: In their 30’s Mixed white and black Caribbean (13%) or mixed white and black African (12%) Little difference between men and women Previous analysis (using Datanet) demonstrated that those less likely to have adequate BP control were: Younger people (<65) Black African and Caribbean groups Men With a significant proportion of patients who were uncontrolled were recorded as only having one or two antihypertensive medications suggesting optimisation may not have occurred.

Part two Identification of patients Practices were asked to identify ALL patients with a systolic blood pressure >160mmHg and/or a diastolic blood pressure >100mmHg. Patients who had been diagnosed in the previous 6 months and those on the palliative care register were excluded. Those diagnosed in previous 6 months excluded as looking at persistently uncontrolled patients – they will still be in phase of initiating/titrating treatment. Those on palliative care register excluded as tight BP control not required – aim to avoid unnecessary polypharmacy and medication side effects in these patients Some patients were identified from the register (and prior readings) as having a SBP 160 or over and/or a DBP 100 and over but on attending for a review actually had BP’s below both of these thresholds. Data from these patients was still collected. Develop practice hypertension action plan Practices were then asked to develop and implement a local hypertension action plan

Management options 1. Review by GP and practice nurse Medicines optimisation Support patients with medication adherence 2. Review at the specialist led virtual clinic 3. Refer to community hypertension service 4. Refer to hospital hypertension service Further investigations As seen, wherever the patient is seen or managed the same will be offered. Patients will be stratified based on complexity Differences are : VC: specialist CVD pharmacists provide expertise Community clinic: specialist CVD pharmacists provide expertise and have longer appointment slots to dedicate to patients who require more time to discuss their medicines Hospital clinic: Consultants/Specialist Doctors provide the expertise and have access to specialist investigations for those patients who need

Sample characteristics 45 practices submitted data for 1,982 patients All data given in percentages

Sample characteristics 45 practices submitted data for 1,982 patients All data given in percentages

Results 26 patients did not respond to invitations for an initial BP review from the practices A further 445 (22.5%) failed to attend for follow up readings despite repeated invitations from the practices Significant proportion of patients discussed at VC not engaging with services (14%)

Results Systolic BP 172.9 147.9 - 25.0 14.5 Diastolic BP 106.5 89.8 Patients with initial SBP ≥160 (n=1231) Initial mean BP Final mean BP Difference (n) Difference (%) Systolic BP 172.9 147.9 - 25.0 14.5 Patients with initial DBP ≥100 (n=648) Initial mean BP Final mean BP Difference (n) Difference (%) Diastolic BP 106.5 89.8 16.7 15.7

Results Age Ethnicity Sex All age groups improved Older age group improved more than younger age groups Younger age groups more likely to not engage with intervention compared to older age groups Ethnicity All ethnic groups improved Improvement appears greatest in South Asian and other ethnic groups compared to black groups Other ethnic groups less likely to engage with intervention compared to white groups Sex Both sexes improved but improvement was greater in females compared to males Males less likely to engage with intervention Other is that patients who were discussed at virtual clinic and those that were not had similar reductions in BP

Targets Target % of patients meeting criteria at baseline % of patients meeting criteria at endpoint NICE systolic BP for under 80’s (<140mmHg) 3.4 39.6 QOF systolic BP (<150mmHg) 9.6 61.7 NICE/QOF diastolic BP (<90mmHg) 33.2 68.5 As noted previously – some people included did have a first reading of BP that did not meet thresholds but were still included. Actions suggested at virtual clinics: Titration of current meds: 21.3% Within class change in meds: 2.3% Initiation of new medication: 32.7% Review concordance: 21.6% Lifestyle: 9.7% 24 hour monitoring: 5.6% Community hypertension clinic referral: 4.0% Secondary care referral: 4.5% Any referral: 8.5% SUGGESTS ROOM FOR MEDICINES OPTIMISATION NICE = National Institute for Health and Care Excellence QOF = Quality and Outcomes Framework

Conclusions (1) For those that are engaged in primary care services: Those with initial systolic blood pressure ≥160mmHg achieved an average reduction of 25mmHg = 55-70% reduction in risk of stroke = 45-55% reduction in risk of coronary events M R Law et al. BMJ 2009;338:bmj.b1665 Those with initial diastolic blood pressure ≥100mmHg achieved an average reduction of 16.7mmHg There were no differences in outcomes achieved based on age, gender or ethnicity Achieved huge reductions in blood pressure and reduced the risk of mortality from ischaemic heart disease and stroke in our population BUT we still have more progress to make Need to work on: Engagement of those who are not engaging Continuing work on medicines optimisation and look at reducing the variation across practices Increasing prevalence and find the missing patients

Conclusions (2) Challenges: Future direction: Still a proportion of people with high blood pressure who are not engaging with general practices. Further data analysis is being undertaken to assess any underlying inequalities in this group Future direction: Exploring inequalities in engagement with primary care services Continuing work on optimising medicines for those with hypertension Exploring options to increase the prevalence of hypertension